BVL3572S inhibits HisC and AlaA, exploiting vitamin B6 dependency to kill Mycobacterium tuberculosis

paru le: 04/09/2026

Edoo Z, Lenne-Delmotte A, Grosse C, Devaere M, Michel M, Caron G, Anoz-Carbonell E, Djaout K, Frita R, Gaudin C, Hofmann L, Lecher S, Megalizzi V, Michelotti A, Rengel D, Rouan P, Slupek S, Tawk L, Antoine R, Kulyk H, Dale G, Guilhot C, Willand N, Lippens G, Wintjens R, Baulard AR. BVL3572S inhibits HisC and AlaA, exploiting vitamin B6 dependency to kill Mycobacterium tuberculosis. Cell Chem Biol. 2026 Aug 11:S2451-9456(26)00281-3. doi: 10.1016/j.chembiol.2026.07.008. Epub ahead of print. PMID: 42580344.

Tuberculosis remains the leading cause of death from a single infectious agent, and rising multi-drug resistance in Mycobacterium tuberculosis (Mtb) underscores the urgent need for new antibiotics. Here, we characterize BVL3572S, a hydroxamic acid-containing compound that is bactericidal against Mtb.

See the entire article